Recombinant Filgrastim (BK0023) Pharmacodynamics and Pharmacokinetics After Single and Multiple Escalating Doses in an Equivalence Study in Healthy Men

Andrea F D Di Stefano, Gaia Spinetti, Antonio Rusca, Milko M. Radicioni, Luca Loprete, Domenica M G Lamparelli, Jutta Michael Hepp, Davide Crobu, Rodolfo Schrepfer, Giancarlo Tonon

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and objectives: The new filgrastim formulation, BK0023, whose synthesis method is patented, was tested in a phase I clinical study that was aimed at investigating the pharmacodynamic and pharmacokinetic equivalence and the safety of BK0023 in healthy male subjects. Methods: Single and multiple escalating doses were administered to healthy male volunteers according to a double-blind, randomised, two-way crossover design. Thirty-two subjects received subcutaneous filgrastim 2.5 µg/kg/day for 7 consecutive days in each period, 36 subjects received 5 µg/kg/day for 7 days in each period, and 22 subjects received 10 µg/kg/day for 5 days. Absolute neutrophil count (ANC) and CD34+ cell count were measured in whole blood as primary and secondary pharmacodynamic parameters. Filgrastim concentrations were measured in serum to calculate the primary pharmacokinetic parameters. Results: The maximum ANC and the area under the curve of the ANC after the first dose and to the end of treatment satisfied the equivalence criterion (95 % confidence intervals within 85–115 or 85–117 % in case of log-transformation). At all three dose regimens, BK0023 was also bioequivalent to the reference product in terms of pharmacokinetic profile of serum filgrastim. The frequency of the treatment-emergent adverse events did not differ significantly between treatments, with the most frequent untoward effects being back and bone pain. Conclusions: Equivalence could be established using both the baseline-adjusted values and the original unadjusted values. The tested formulation at all three dose regimens was also bioequivalent to the reference product in terms of pharmacokinetic profile.

Original languageEnglish
Pages (from-to)533-545
Number of pages13
JournalClinical Drug Investigation
Volume35
Issue number9
DOIs
Publication statusPublished - Aug 7 2015

Fingerprint

Pharmacokinetics
Neutrophils
Healthy Volunteers
Back Pain
Serum
Cross-Over Studies
Area Under Curve
Therapeutics
Cell Count
Confidence Intervals
Safety
Bone and Bones
Filgrastim

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Recombinant Filgrastim (BK0023) Pharmacodynamics and Pharmacokinetics After Single and Multiple Escalating Doses in an Equivalence Study in Healthy Men. / Di Stefano, Andrea F D; Spinetti, Gaia; Rusca, Antonio; Radicioni, Milko M.; Loprete, Luca; Lamparelli, Domenica M G; Michael Hepp, Jutta; Crobu, Davide; Schrepfer, Rodolfo; Tonon, Giancarlo.

In: Clinical Drug Investigation, Vol. 35, No. 9, 07.08.2015, p. 533-545.

Research output: Contribution to journalArticle

Di Stefano, AFD, Spinetti, G, Rusca, A, Radicioni, MM, Loprete, L, Lamparelli, DMG, Michael Hepp, J, Crobu, D, Schrepfer, R & Tonon, G 2015, 'Recombinant Filgrastim (BK0023) Pharmacodynamics and Pharmacokinetics After Single and Multiple Escalating Doses in an Equivalence Study in Healthy Men', Clinical Drug Investigation, vol. 35, no. 9, pp. 533-545. https://doi.org/10.1007/s40261-015-0310-x
Di Stefano, Andrea F D ; Spinetti, Gaia ; Rusca, Antonio ; Radicioni, Milko M. ; Loprete, Luca ; Lamparelli, Domenica M G ; Michael Hepp, Jutta ; Crobu, Davide ; Schrepfer, Rodolfo ; Tonon, Giancarlo. / Recombinant Filgrastim (BK0023) Pharmacodynamics and Pharmacokinetics After Single and Multiple Escalating Doses in an Equivalence Study in Healthy Men. In: Clinical Drug Investigation. 2015 ; Vol. 35, No. 9. pp. 533-545.
@article{325f00f3624945f0b21ce81a39845da6,
title = "Recombinant Filgrastim (BK0023) Pharmacodynamics and Pharmacokinetics After Single and Multiple Escalating Doses in an Equivalence Study in Healthy Men",
abstract = "Background and objectives: The new filgrastim formulation, BK0023, whose synthesis method is patented, was tested in a phase I clinical study that was aimed at investigating the pharmacodynamic and pharmacokinetic equivalence and the safety of BK0023 in healthy male subjects. Methods: Single and multiple escalating doses were administered to healthy male volunteers according to a double-blind, randomised, two-way crossover design. Thirty-two subjects received subcutaneous filgrastim 2.5 µg/kg/day for 7 consecutive days in each period, 36 subjects received 5 µg/kg/day for 7 days in each period, and 22 subjects received 10 µg/kg/day for 5 days. Absolute neutrophil count (ANC) and CD34+ cell count were measured in whole blood as primary and secondary pharmacodynamic parameters. Filgrastim concentrations were measured in serum to calculate the primary pharmacokinetic parameters. Results: The maximum ANC and the area under the curve of the ANC after the first dose and to the end of treatment satisfied the equivalence criterion (95 {\%} confidence intervals within 85–115 or 85–117 {\%} in case of log-transformation). At all three dose regimens, BK0023 was also bioequivalent to the reference product in terms of pharmacokinetic profile of serum filgrastim. The frequency of the treatment-emergent adverse events did not differ significantly between treatments, with the most frequent untoward effects being back and bone pain. Conclusions: Equivalence could be established using both the baseline-adjusted values and the original unadjusted values. The tested formulation at all three dose regimens was also bioequivalent to the reference product in terms of pharmacokinetic profile.",
author = "{Di Stefano}, {Andrea F D} and Gaia Spinetti and Antonio Rusca and Radicioni, {Milko M.} and Luca Loprete and Lamparelli, {Domenica M G} and {Michael Hepp}, Jutta and Davide Crobu and Rodolfo Schrepfer and Giancarlo Tonon",
year = "2015",
month = "8",
day = "7",
doi = "10.1007/s40261-015-0310-x",
language = "English",
volume = "35",
pages = "533--545",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "9",

}

TY - JOUR

T1 - Recombinant Filgrastim (BK0023) Pharmacodynamics and Pharmacokinetics After Single and Multiple Escalating Doses in an Equivalence Study in Healthy Men

AU - Di Stefano, Andrea F D

AU - Spinetti, Gaia

AU - Rusca, Antonio

AU - Radicioni, Milko M.

AU - Loprete, Luca

AU - Lamparelli, Domenica M G

AU - Michael Hepp, Jutta

AU - Crobu, Davide

AU - Schrepfer, Rodolfo

AU - Tonon, Giancarlo

PY - 2015/8/7

Y1 - 2015/8/7

N2 - Background and objectives: The new filgrastim formulation, BK0023, whose synthesis method is patented, was tested in a phase I clinical study that was aimed at investigating the pharmacodynamic and pharmacokinetic equivalence and the safety of BK0023 in healthy male subjects. Methods: Single and multiple escalating doses were administered to healthy male volunteers according to a double-blind, randomised, two-way crossover design. Thirty-two subjects received subcutaneous filgrastim 2.5 µg/kg/day for 7 consecutive days in each period, 36 subjects received 5 µg/kg/day for 7 days in each period, and 22 subjects received 10 µg/kg/day for 5 days. Absolute neutrophil count (ANC) and CD34+ cell count were measured in whole blood as primary and secondary pharmacodynamic parameters. Filgrastim concentrations were measured in serum to calculate the primary pharmacokinetic parameters. Results: The maximum ANC and the area under the curve of the ANC after the first dose and to the end of treatment satisfied the equivalence criterion (95 % confidence intervals within 85–115 or 85–117 % in case of log-transformation). At all three dose regimens, BK0023 was also bioequivalent to the reference product in terms of pharmacokinetic profile of serum filgrastim. The frequency of the treatment-emergent adverse events did not differ significantly between treatments, with the most frequent untoward effects being back and bone pain. Conclusions: Equivalence could be established using both the baseline-adjusted values and the original unadjusted values. The tested formulation at all three dose regimens was also bioequivalent to the reference product in terms of pharmacokinetic profile.

AB - Background and objectives: The new filgrastim formulation, BK0023, whose synthesis method is patented, was tested in a phase I clinical study that was aimed at investigating the pharmacodynamic and pharmacokinetic equivalence and the safety of BK0023 in healthy male subjects. Methods: Single and multiple escalating doses were administered to healthy male volunteers according to a double-blind, randomised, two-way crossover design. Thirty-two subjects received subcutaneous filgrastim 2.5 µg/kg/day for 7 consecutive days in each period, 36 subjects received 5 µg/kg/day for 7 days in each period, and 22 subjects received 10 µg/kg/day for 5 days. Absolute neutrophil count (ANC) and CD34+ cell count were measured in whole blood as primary and secondary pharmacodynamic parameters. Filgrastim concentrations were measured in serum to calculate the primary pharmacokinetic parameters. Results: The maximum ANC and the area under the curve of the ANC after the first dose and to the end of treatment satisfied the equivalence criterion (95 % confidence intervals within 85–115 or 85–117 % in case of log-transformation). At all three dose regimens, BK0023 was also bioequivalent to the reference product in terms of pharmacokinetic profile of serum filgrastim. The frequency of the treatment-emergent adverse events did not differ significantly between treatments, with the most frequent untoward effects being back and bone pain. Conclusions: Equivalence could be established using both the baseline-adjusted values and the original unadjusted values. The tested formulation at all three dose regimens was also bioequivalent to the reference product in terms of pharmacokinetic profile.

UR - http://www.scopus.com/inward/record.url?scp=84941183891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941183891&partnerID=8YFLogxK

U2 - 10.1007/s40261-015-0310-x

DO - 10.1007/s40261-015-0310-x

M3 - Article

VL - 35

SP - 533

EP - 545

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 9

ER -